Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07572513

Slowly Digestible Carbohydrates for GLP-1 Secretion

The goal of this clinical trail is to learn if the hormone, glucagon-like peptide-1 (GLP-1), is stimulated by slowly digestible carbohydrates (SDCs) in healthy adults. In the current study, researchers will observe the amount of SDC that results in clinically meaningful levels of GLP-1, shown by an increase in feelings of fullness and a decrease in hunger, and how long an elevated level of GLP-1 lasts after starch consumption. Researchers aim to address two questions: What amount of SDC maximizes GLP-1-mediated satiety, and does the impact to satiety continue in a second meal? The overall goal is to maximize ileal-digesting SDC's potential use as a food-based agent for weight loss.

Researchers will compare 20, 40, and 60 g of raw corn starch compared to a maltodextrin control on total plasma GLP-1 concentrations, insulin, and blood glucose at baseline and 15, 30, 60, 90, 120, and 180 minutes post-consumption of SDC. Researchers will also measure satiety at baseline, 60, 120, 180 minutes and after a second meal.

There will be a total of 4 study visits with a least a 7-day break between visits. At each study visit, participants will:

* Consume a randomized test beverage (SDC or maltodextrin) * Receive a blood draw at 7 timepoints over 3 hrs * Take a satiety questionnaire 5 times over 3 hrs * Consume a standardized lunch 3 hrs after the test beverage consumption

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Blood Glucose GLP-1 Healthy Participant Study Satiety Second Meal Intake

Age range

18 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Clinical Research Center at Purdue University

West Lafayette, Indiana, 47907, United States

Location status: Recruiting

Location contact

Cheryl Armstrong, Ph.D.

CONTACT

[email protected]

765-496-6275

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy population
  • BMI between 18.5 and 24.9 kg/m2
  • Adults 18 - 45 years old
  • Men or women
  • Able to read/speak English
  • Fasting blood glucose levels ≤100 mg/dL
  • HbA1c ≤ 5.7%

Exclusion criteria

  • Participants with 18 > Years of Age > 45 will be excluded.
  • Subjects with 18.5 kg/m² > BMI > 24.9 kg/m² will be excluded.
  • Diabetic individuals will be excluded.
  • Individuals with history of gastrointestinal disease will be excluded from the study.
  • Pregnant or nursing women will also be excluded.
  • Individuals taking GLP-1 medications, or on weight-loss diets or restrictive eating patterns.
  • Individuals suffering from dairy or gluten intolerance or allergies will be excluded.

Treatment and study plan

Maltodextrin (Placebo)

Dietary Supplement

75 g of maltodextrin diluted in 200 mL of water, taken once at a study visit

Other names: Control

Raw Corn Starch

Dietary Supplement

Quantity of raw corn starch will vary between low, medium, and high-dose treatment arms (20, 40, 60 g respectively). Each treatment will total 75 g using maltodextrin to account for mass difference (55, 35, 15 g respectively).

Other names: Slowly-Digestible Carbohydrate, Ileal-Digesting Starch

Primary outcomes

  1. Total GLP-1 Secretion

    Time frame: From baseline and 15, 30, 60, 90, 120, and 180 minutes post-consumption of treatment for each participant over the course of the 4 arms.

    To determine the impact of 20, 40, 60 g of SDC compared to a maltodextrin control on total plasma GLP-1 concentrations at baseline and 15, 30, 60, 90, 120, and 180 minutes post-consumption of SDC. Assessed via spun blood plasma and ELISA Total GLP-1 Kits.

Secondary outcomes

  1. Satiety

    Time frame: From baseline, 60, 120, 180 minutes and after a second meal for each participant over the course of the 4 arms.

    Measure satiety at baseline, 60, 120, 180 minutes and after a second meal via satiety questionnaires

  2. Blood Glucose

    Time frame: From baseline, and 15, 30, 60, 90, 120, and 180 minutes post-consumption for each participant over the course of the 4 arms

    To determine the impact of 20, 40, 60 g of SDC compared to a maltodextrin control on total plasma glucose concentrations at baseline and 15, 30, 60, 90, 120, and 180 minutes post-consumption of SDC. Assessed via spun blood serum.

  3. Insulin

    Time frame: From baseline, and 15, 30, 60, 90, 120, and 180 minutes post-consumption for each participant over the course of the 4 arms

    To determine the impact of 20, 40, 60 g of SDC compared to a maltodextrin control on insulin concentrations at baseline and 15, 30, 60, 90, 120, and 180 minutes post-consumption of SDC. Assessed via spun blood plasma.

Study contacts

Contact information is provided by the study sponsor or research team.

Bruce R Hamaker, Ph.D.

CONTACT

[email protected]

765-494-5668

Erica de Jong, B.s.

CONTACT

[email protected]

7654963802

Sponsors and collaborators

Lead sponsor

Purdue University

Other

Registry information

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
May 7, 2026
Registry last updated
May 7, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.